Report : Europe Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)Â Â
Diagnostics and Research Laboratories Segment to Dominate Europe Cervical Cancer Diagnostic Testing Market During 2021–2028
According to a new market research study on “Europe Cervical Cancer Diagnostic Testing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and Service Provider” is expected to reach US$ 1,881.38 million by 2028 from US$ 1,368.86 million in 2021. The market is estimated to grow at a CAGR of 4.6% from 2021 to 2028. The report provides trends prevailing in the Europe cervical cancer diagnostic testing market along with the drivers and restraints pertaining to the market growth. Accelerating HPV infections and growing prevalence of cervical cancer are the major factor driving the growth of the Europe cervical cancer diagnostic testing market. However, less awareness about the diagnosis and treatment methods hinders the growth of Europe cervical cancer diagnostic testing market.
In case of COVID-19, Europe is highly affected specially the UK. The epidemic has caused a reduction in various medical procedures such as screening, follow-up, HPV triage tests, invasive diagnostic, and treatment of cervix-related indications. There is a need to create awareness among women about the advantages of early cervical cancer screening. The unwillingness of the patients to take the test is expected to have an undesired impact on the market in the region. However, global players such as Hologic Inc. in November 2021 launched Genius Digital Diagnostics System and are now commercially available in Europe. Thus, such active involvement of the international market players in the regional markets is expected to positively impact the region's market.
The Europe cervical cancer diagnostic testing market has been segmented based on type, service provider, and country. Based on type, the market has been segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, and others. The PAP testing segment dominated the market in 2020 and HPV testing segment is expected to be fastest growing during forecast period. Based on service provider, the market has been segmented into diagnostics and research laboratories, hospitals and clinics, specialty clinics, and home care services. The diagnostics and research laboratories segment dominated the market in 2020 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into the UK, Germany, France, Italy, Spain, and rest of Europe.
Abbott; BD; Cooper Companies, Inc.; DYSIS Medical Inc; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among the leading companies in the Europe cervical cancer diagnostic testing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, BD won approval of COR PX/GX System from the U.S. Food and Drug Administration, and is now available in U.S. The system has been available in Europe since 2019 and is ready for use in centralized labs that can handle high-volume processing and increases efficiency.
Europe Cervical Cancer Diagnostic Testing Market, By Country, 2020 and 2028 (%)
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org